🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huzhou
Clinical trial register · China

Clinical Trials in Huzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine16 Eli Lilly and Company6 Yu jiren3 Novo Nordisk A/S2 Capital Medical University2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Huzhou

40 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
NCT07800572Acute Ischemic Stroke
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
DrugAZD6234
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Not yet open
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD
NCT07665359Chronic Obstructive Pulmonary Disease (COPD)
DrugsTMP/SMX·Trimethoprim-sulfamethoxazole
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
Boehringer Ingelheim
Phase 2
342
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Recruiting
IASO-782 in Systemic Lupus Erythematosus
NCT07483346SLE - Systemic Lupus Erythematosus
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
20
Hangzhou, Huzhou, Jiaxing
2026-05-26
Not yet open
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07625514Gout Flare
DrugFirsekibart
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
264
Fuzhou, Hangzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-07
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-05-06
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Beijing, Nanjing, Suzhou, Zhenjiang, Huzhou
2026-05-05
Not yet open
Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial
NCT07616531Gout Flares
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
118
Hangzhou, Fuzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-01
Not yet open
Effect of taVNS on Perioperative Anxiety in Major Abdominal Surgery
NCT07495163Perioperative Anxiety, Major Abdominal Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
282
Huzhou, Jiaxing, Meicheng, Hangzhou
2026-05-01
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-04-29
Active, closed
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)
NCT07513233Acute Ischemic Stroke
Capital Medical University
Phase 1
92
Zhangzhou, Jiuquan, Yulin, Shangqiu, Xuzhou, Beijing, Zibo, Huzhou
2026-04-28
Not yet open
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
NCT07518810Multiple System Atrophy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
150
Nanning, Huzhou, Jiaxing, Ningbo, Taizhou, Beijing
2026-04-10
Recruiting
Utility of Whole Genome Sequencing in Fetuses With Abnormal Ultrasound Findings
NCT07606989Prenatal Diagnosis, Fetal Diseases
Women's Hospital School Of Medicine Zhejiang University
Observational
1,000
Hangzhou, Huzhou, Quzhou, Shaoxing
2026-03-12
Recruiting
Ultrasound-Guided Intra-Articular vs Gluteal Intramuscular Corticosteroid Injection for Frozen Shoulder
NCT07416916Frozen Shoulder
DrugCompound betamethasone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
528
Shanghai, Hangzhou, Huzhou, Jinhua, Ningbo, Shanhu
2026-02-23
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
NCT07508618Persistent Atrial Fibrillation
Sir Run Run Shaw Hospital
Phase 4
846
Hangzhou, Huzhou, Ningbo
2026-02-09
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou, Jining
2026-02-09
Recruiting
A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease
NCT07493603Coronary Heart Disease, Coronary Artery Disease, Atheroscleroses
Xia Liang
Phase 1/2
30
Huzhou
2026-01-16
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
NCT07114120Bronchiectasis, COPD
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
214
Hangzhou, Huzhou, Jinhua, Yueqing, Zhoushan
2025-07-14
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
NCT06375005Diffuse Cutaneous Systemic Sclerosis
DrugsMycophenolate Mofetil·Telitacicept
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
DrugVedolizumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT06520163Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
DrugsPEG-rhG-CSF·G-Csf·Cytarabine·Etoposide
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176Multiple Myeloma, Hematopoietic Stem Cell Mobilization
DrugsPegfilgrastim·G-Csf·Cytarabine·Etoposide
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
NCT06537115Sarcopenia
Zhejiang Provincial People's Hospital
Phase 4
450
Hangzhou, Huzhou, Taizhou, Zhoushan
2024-06-16
Not yet open
Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction
NCT05994872Anterior Cruciate Ligament Injuries
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis
NCT06074679Cholecystectomy, Laparoscopic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
600
Huangshan City, Hangzhou, Huzhou, Lishui, Meicheng
2023-10-01
Recruiting
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784Severe Pneumonia
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
DrugsS1·Oxaliplatin·Tislelizumab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
DrugsS1·Oxaliplatin·Tislelizumab
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
DrugsFLOT·Trastuzumab·Tislelizumab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
NCT05742425Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type
DrugSerplulimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Huzhou
2023-03
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/huzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Huzhou.

How many clinical trials are recruiting in Huzhou?

26 of the 40 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huzhou), 40 studies
PhaseStudiesRecruitingShare
Phase 211827.5%
Not applicable9122.5%
Phase 38720%
Phase 45512.5%
Observational337.5%
Phase 1215%
Phase 1/2112.5%
Phase 2/3102.5%

Most active sponsors

Lead sponsors with the most studies (Huzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine167
Eli Lilly and Company66
Yu jiren31
AstraZeneca22
Capital Medical University21
Novo Nordisk A/S21
The Affiliated People's Hospital of Ningbo University22
Boehringer Ingelheim10
First Affiliated Hospital of Zhejiang University11
Shanghai IASO Biotechnology Co., Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.